Acthar is believed to work with both the immune system and central nervous system. It’s also believed to have steroid-independent immunomodulatory and anti-inflammatory properties in addition to its steroid-dependent properties through cortisol release.3-16
Acthar and melanocortin receptors (MCRs)
*While the exact mechanism of action of Acthar is unknown, further investigation is being conducted. This information is based on nonclinical data, and the relationship to clinical benefit is unknown.
In a study of 18 healthy subjects, total serum cortisol-equivalent exposure as measured by area under the effect curve (AUEC) was significantly higher following IVMP compared with Acthar dosing (133,310 vs 3641 ng/mL*hr, P<0.001).34
As this was a healthy-subject, open-label study with no placebo control, the clinical relevance of differences in tolerability is unknown and remains to be investigated for patient populations.
Mean ± SEM; n=17 for IVMP and n=18 for Acthar.
Total steroid exposure (based on cortisol equivalence) = AUEC cortisol + (MP AUC x Potency Factor of 5).
Abbreviation: AUC, area under the curve; AUEC, area under the effect curve.
†P<0.001 day 5.
In this MS conversation, Dr. Christopher LaGanke describes Acthar’s potential MOA.
H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.
Warnings and Precautions
Please see full Prescribing Information.